Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 50,013

Document Document Title
WO/2018/069855A1
The object of the invention is xanthohumol or its physiologically acceptable salt or a molecular complex or a metal complex for use in the treatment, prophylaxis or prevention of the haemorrhoidal disease or other diseases of the anal ar...  
WO/2018/071701A1
In one aspect, the invention provides methods for reducing proteinuria in a human subject suffering, or at risk of developing Immunoglobulin A Nephropathy (IgAN). The methods comprise the step of administering, to a subject in need there...  
WO/2018/069936A1
An amorphous form of betrixaban maleate and process for the preparation of the same are disclosed. A solid dispersion of amorphous betrixaban maleate with pharmaceutically acceptable excipients and processes for the preparation of the sa...  
WO/2018/071678A1
Provided herein are high strength/high drug load tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)me thoxy)benzaldehyde ("Compound 1"), dispersible tablets comprising Compound 1, processes of manufacturing suc...  
WO/2018/064953A1
Use of isopropyl β-(3,4-dihydroxyphenyl)-α-hydroxypropionate (IDHP) in the preparation of a drug or a health product for prevention and treatment of coronary atherosclerosis diseases. The IDHP can also be used to inhibit platelet aggre...  
WO/2018/067874A1
In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of red blood cells or a tissue, such as bone, cartilage, muscle, fat, and/or neuronal tissue. The present inventi...  
WO/2018/063025A1
The invention relates to medicine and veterinary science, and is a pharmaceutical composition which contains iron(II) sulphate and is intended for the treatment of iron deficiency anaemia, characterised in that it additionally contains i...  
WO/2018/059331A1
The present invention relates to a polyamide compound and a use thereof; specifically, the present invention relates to a type of polyamide compound (which preferably contains one or more amide bonds formed by the condensation of same or...  
WO/2018/064119A1
Disclosed herein are small molecule calpain modulator compositions, pharmaceutical compositions, the use and preparation thereof.  
WO/2018/064557A1
The present disclosure relates to substituted fused bi- or tri- heterocyclic compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating a disorder (e.g., sickle cell a...  
WO/2018/060311A1
The present invention relates to pharmaceutical compositions comprising a controlled-release PTH compound or a pharmaceutically acceptable salt, hydrate, or solvate thereof, for use in a method of treating, controlling, delaying or preve...  
WO/2018/053634A1
The disclosure concerns a class of hemoglobin based oxygen carriers (HBOCs) comprising a first hemoglobin protein cross-linked by a chemical reaction that is followed by a strain-promoted alkyne-azide cycloaddition (SPAAC) reaction or by...  
WO/2018/054059A1
The present invention belongs to the technical field of industrial microbiology. Disclosed is a method of producing surfactin by applying Bacillus amyloliquefaciens. By applying Bacillus amyloliquefaciens of CGMCC No.12593 obtained by sc...  
WO/2018/056019A1
The purpose of the present invention is to provide: a method for producing a sustained-release drug that makes it possible to load a medicinal ingredient on a porous material comprising a bioabsorbable polymer and control the release rat...  
WO/2018/053190A1
The application provides methods of treating or reducing thrombocytopenia, leukopenia, anemia, or neutropenia in a patient in need thereof, comprising the step of administering an effective amount of a compound selected from Compounds 1-...  
WO/2018/052827A1
Factor VII glycoproteins having glycosylation patterns that render them suitable for therapeutic indications such as postpartum hemorrhage requiring short half -life and rapid and high clearance are disclosed with related methods of maki...  
WO/2018/053234A1
In certain aspects, the present invention provides compositions and methods for altering iron metabolism to increase red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.  
WO/2018/053288A1
Improved platelet producing megakaryocytes and methods of use thereof are disclosed.  
WO/2018/045906A1
Provided is a 2-acylaminothiazole derivative, or a pharmaceutically acceptable salt, ester, solvate, hydrate, isomer, or any crystal form or racemate thereof, or metabolite forms thereof, or mixtures thereof, for therapeutic use in the m...  
WO/2018/048477A1
The present invention provides an imaging agent for identifying sites of platelet activation. As such, it provides methods for identifying thrombus formation in a human or non-human animal, methods for making the imaging agent, and kits ...  
WO/2018/045907A1
The present invention relates to a novel 2-acylaminothiazole derivative. The present invention also relates to a method for preparing the novel 2-acylaminothiazole derivatives and intermediates thereof, as well as to a pharmaceutical com...  
WO/2018/047813A1
An objective of the present invention is to provide an effective pharmaceutical composition or a dosage regimen for preventing and/or treating bleeding, a disease accompanying bleeding, or a disease caused by bleeding. The inventors disc...  
WO/2018/046401A1
The present invention relates to crystalline salts of betrixaban and processes for their preparation. More specifically, it relates to crystalline betrixaban hydrochloride, crystalline betrixaban citrate and to crystalline form B of betr...  
WO/2018/048346A1
The present invention relates to substituted azole derivatives in combination with cytokines in the ex vivo expansion of CD34+ hematopoietic stem and progenitor cells (HSPC) in a biological sample, more particularly the expansion of thes...  
WO/2018/047894A1
Provided is a novel antibody. According to the present invention, a monoclonal antibody or a binding fragment thereof binds to domain 3 of a human LAG-3, and has the properties described in (i) and (vi) and one or more of the properties ...  
WO/2018/041122A1
The present invention relates to an oxopicolinamide derivative, a preparation method therefor and the pharmaceutical use thereof. In particular, the present invention relates to the oxopicolinamide derivative as shown in the general form...  
WO/2018/041750A1
The invention relates to a sulfated polysaccharide extracted from a red alga or a pharmaceutically acceptable salt thereof, in which the sulfate content is less than or equal to 20 mass % of the polysaccharide. The invention also relates...  
WO/2018/042320A1
The present application relates to novel acid addition salts of Betrixaban and processes for their preparation thereof. It further relates to crystalline forms including its solvates and hydrates of Betrixaban novel acid addition salts. ...  
WO/2018/039754A1
The present abstract relates to an invention patent application for a food factor-based formulation, products produced therewith and method for producing same, pertaining to the field of products of food and medical-pharmaceutical use, d...  
WO/2018/045045A1
Herein, 8-substituted guanine and/or 8-substituted guanosine compounds are used in methods to treat hypertension (such as systemic or pulmonary hypertension), stroke, diabetes, and/or patients in need of a diuretic. In addition, 8-substi...  
WO/2018/039094A1
The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or ...  
WO/2018/039386A1
The invention relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): (I), wherein L1,...  
WO/2018/036117A1
The present invention provides a tissue factor (TF) monoclonal antibody and a preparation method therefor. The monoclonal antibody provided by the present invention can specifically bind with a TF antigen, has high affinity and low immun...  
WO/2018/036473A1
An anti-CTLA4 (cytotoxic T lymphocyte associated antigen 4) and anti-PD-1 (programmed cell death 1) bifunctional antibody, a pharmaceutical composition thereof and use thereof. Particularly, the anti-CTLA4 and anti-PD-1 bifunctional anti...  
WO/2018/032786A1
A hyperglycosylated recombinant human coagulation factor IX (FIX) fusion protein, a preparation method therefor, and use thereof. The fusion protein sequentially comprises, from N- to C-terminus, a human FIX, a flexible peptide linker, a...  
WO/2018/033033A1
Use of a fullerene structure in preparation of a medicament for treating anemia and complications thereof. The fullerene structure comprises at least one of: fullerene, a water-soluble modified form of fullerene, a fullerene composition ...  
WO/2018/032637A1
A highly glycosylated human blood-clotting factor VIII (FVIII) fusion protein, and a manufacturing method and application of same. The fusion protein comprises, from the N-terminus to the C-terminus, a human (FVIII), a flexible peptide c...  
WO/2018/032639A1
The present invention discloses a highly glycosylated and activated human blood-clotting factor VII (FVIIa) fusion protein, and a manufacturing method and application of same. The fusion protein comprises, from the N-terminus to the C-te...  
WO/2018/033165A1
A polymer-metal oxide complex, comprising a metal oxide particle located at the core and a polymer modified on the surface of the metal oxide particle, the polymer being provided with functional groups capable of bonding with a metal in ...  
WO/2018/027169A1
The disclosure provides compositions and methods for treating, ameliorating, and/or preventing a vaso-occlusive crisis (VOC) in a subject suffering from sickle cell disease (SCD). The disclosure also provides compositions and methods for...  
WO/2018/024873A1
The present invention relates to pharmaceutical formulations comprising the C1 esterase inhibitor (C1-INH), exhibiting a higher stability for prolonged storage and a reduced formation of aggregates of said esterase inhibitor (C1-INH) upo...  
WO/2018/024224A1
A nitrogen-containing tricyclic compound which acts as modulator of FXR, or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and the ...  
WO/2018/019911A1
The present invention is related to a combination useful in the prevention and/or treatment of red blood cell disorders, in particular, acute and chronic complications associated with red blood cell dysfunction, increased red blood cell ...  
WO/2018/019296A1
Disclosed is an aminopyrazine compound represented by formula (I), or a pharmaceutically acceptable salt or an isomer thereof. The aminopyrazine compound has prostaglandin I2 (PGI2) receptor agonist activity and is used as an IP receptor...  
WO/2018/022762A1
In part, the present disclosure relates methods for treating, preventing, or reducing the progression rate and/or severity of myelofibrosis or one or more complications of myelofibrosis (extramedullary hematopoiesis, splenomegaly, anemia...  
WO/2018/017605A1
An organ-on-a-chip microfluidic device is disclosed that mimics a human lymph node and/or human lymphoid tissue. The device can include cells from human blood and lymphatic tissue, include an extracellular matrix for the development of i...  
WO/2018/015531A1
A precursor composition for the preparation of a dialysis fluid, the precursor composition comprising at least a glucose component, an acid component, and an amino acid component, wherein the amino acid component comprises Valine, Isoleu...  
WO/2018/013770A1
Disclosed are compounds of Formula (I) to (IV): [INSERT CHEMICAL STRUCTURE HERE] or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof. Also disclosed are methods of using such compounds as PAR4 inhibi...  
WO/2018/013774A1
Disclosed are compounds of Formula (I) to (VIII): (I) (II) (III) (IV) (V) (VI) (VII) (VIII); or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a bicyclic heteroaryl group substituted...  
WO/2018/013915A1
Methods of preventing and/or treating reperfusion injury are provided. The methods involve administering alpha-2-macroglobulin (A2MG) to a subject with ischemia in one or more tissues or organs, in order to prevent or decrease reperfusio...  

Matches 1 - 50 out of 50,013